Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Austrian Fulvestrant Registry: Results From A Prospective Observation Of Fulvestrant In Postmenopausal Patients With Metastatic Breast Cancer

R. Bartsch, B. Mlineritsch, M. Gnant, T. Niernberger, U. Pluschnig, R. Greil, C. Wenzel, P. Sevelda, J. Thaler, M. Rudas, M. Pober, C. Zielinski, G. G. Steger, on behalf of the Austrian Fulvestrant Registry
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Background Endocrine therapy is the preferred treatment in oestrogen- and/or progesterone-receptor (ER/PgR) positive breast cancer. Fulvestrant is a pure ER-antagonist. We present results from the Austrian Fulvestrant Registry. Methods Three-hundred and fifty patients were included. Time to progression (TTP) was defined as primary endpoint. A multivariate analysis was performed to identify factors significantly associated with TTP. Results Fulvestrant was administered as first-line therapy in 26%, second-line in 49%, and third-line or beyond in 25%. TTP was median 7 months. We observed a response in 15% of patients and 41% had SD ≥ 6 months. First-line treatment and non-visceral metastases were associated with longer TTP. One case of pulmonary embolism was reported. Grade 3 toxicities consisted of joint pain (1.4%), nausea (1.4%) and hot flashes (0.3%). Conclusions Fulvestrant was effective and well tolerated. TTP was superior to other trials, due to the large proportion of first-line patients. Activity is apparently independent of Her2-status.
This paper references
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
R. Schiff (2004)
A potent specific pure antiestrogen with clinical potential.
A. Wakeling (1991)
High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients
M. Stendahl (2006)
Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
M. Sun (2001)
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
N. Normanno (2005)
Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
M. Dutertre (2000)
Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?
A. Howell (2006)
Similarities and distinctions in the mode of action of different classes of antioestrogens.
A. Wakeling (2000)
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT
Y. H. Chia (2009)
Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.
S. E. Fawell (1990)
Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme
B. Mlineritsch (2006)
Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy
I. Vergote (2004)
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
S. Chia (2008)
Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study
P. Neven (2007)
Aromatase inhibitors in breast cancer.
I. Smith (2003)
Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.
R. Nicholson (1999)
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
A. Howell (2002)
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
A. Howell (2004)
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
C. Osborne (2002)
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
L. Perey (2007)
Preclinical modeling of endocrine response and resistance
L. Macedo (2008)
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
G. Steger (2005)
Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment
R. Bartsch (2007)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women
J. Robertson (2003)
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
M. Ellis (2003)
Third consensus on medical treatment of metastatic breast cancer
D. Berthold (2006)
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
G. Arpino (2005)
Tamoxifen in the treatment of breast cancer.
C. Osborne (1998)
A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma
E. Bajetta (2002)
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
C. Osborne (2005)
Second consensus on medical treatment of metastatic breast cancer.
S. Bešlija (2007)
Estrogen receptor: current understanding of its activation and modulation.
C. Osborne (2001)
Hormonal therapy for postmenopausal breast cancer: the science of sequencing
W. Miller (2006)
Extending survival with chemotherapy in metastatic breast cancer.
J. O'Shaughnessy (2005)
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
G. Steger (2005)
Fulvestrant in the treatment of HER2-positive advanced breast cancer (ABC)
J. Robertson (2007)
a multinational, double-blind, randomized trial
A Howell (2009)
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
R. Paridaens (2003)
Tamoxifen in the Treatment of Breast Cancer
O. Ck (1998)
Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies
A Howell (2002)
Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis
S. Glück (2001)
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
M. Robertson (2007)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar